An update from Theriva Biologics ( (TOVX) ) is now available.
Theriva Biologics, Inc. announced positive results from their Phase 1b/2a trial of SYN-004 (ribaxamase), a treatment aimed at preventing acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The Data and Safety Monitoring Committee endorsed the continuation of the trial into Cohort 3, where SYN-004 will be used alongside the antibiotic cefepime. The study, which remains blinded, reported no adverse events linked to the drug, and the pharmacokinetics were consistent with expectations, reinforcing the therapeutic potential of SYN-004.
For detailed information about TOVX stock, go to TipRanks’ Stock Analysis page.
